OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies
Michael J. Peluso, Khamal Anglin, Matthew S. Durstenfeld, et al.
Pathogens and Immunity (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 50
Michael J. Peluso, Khamal Anglin, Matthew S. Durstenfeld, et al.
Pathogens and Immunity (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 50
Showing 26-50 of 50 citing articles:
Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019
Gordon Chun‐Kau Chan, Grace Lui, Ngai Sze Wong, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 10, pp. 1406-1412
Open Access | Times Cited: 11
Gordon Chun‐Kau Chan, Grace Lui, Ngai Sze Wong, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 10, pp. 1406-1412
Open Access | Times Cited: 11
Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology
Daniel N. Streblow, Alec J. Hirsch, Jeffrey J. Stanton, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Daniel N. Streblow, Alec J. Hirsch, Jeffrey J. Stanton, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Designing and optimizing clinical trials for long COVID
Julia Moore Vogel, Beth Pollack, E. G. Spier, et al.
Life Sciences (2024) Vol. 355, pp. 122970-122970
Open Access | Times Cited: 3
Julia Moore Vogel, Beth Pollack, E. G. Spier, et al.
Life Sciences (2024) Vol. 355, pp. 122970-122970
Open Access | Times Cited: 3
The Use of Nirmatrelvir-ritonavir in a Case of Breakthrough Long COVID
Linda N. Geng, Hector Bonilla, Robert W. Shafer, et al.
Exploratory Research and Hypothesis in Medicine (2023) Vol. 000, Iss. 000, pp. 394-396
Open Access | Times Cited: 8
Linda N. Geng, Hector Bonilla, Robert W. Shafer, et al.
Exploratory Research and Hypothesis in Medicine (2023) Vol. 000, Iss. 000, pp. 394-396
Open Access | Times Cited: 8
Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
Alison K. Cohen, Toni Wall Jaudon, Eric M. Schurman, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 8
Alison K. Cohen, Toni Wall Jaudon, Eric M. Schurman, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 8
The importance of including Long COVID outcomes when developing novel treatments for acute COVID-19
Chloe Connor, Holly A. Taylor
The Journal of Infectious Diseases (2024)
Open Access | Times Cited: 2
Chloe Connor, Holly A. Taylor
The Journal of Infectious Diseases (2024)
Open Access | Times Cited: 2
Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19
Gangireddy Navitha Reddy, Akanksha Jogvanshi, Sana Naikwadi, et al.
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 9, pp. 943-955
Closed Access | Times Cited: 7
Gangireddy Navitha Reddy, Akanksha Jogvanshi, Sana Naikwadi, et al.
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 9, pp. 943-955
Closed Access | Times Cited: 7
Chronic and delayed neurological manifestations of persistent infections
Darshan Pandya, Tory P. Johnson
Current Opinion in Neurology (2023) Vol. 36, Iss. 3, pp. 198-206
Open Access | Times Cited: 5
Darshan Pandya, Tory P. Johnson
Current Opinion in Neurology (2023) Vol. 36, Iss. 3, pp. 198-206
Open Access | Times Cited: 5
The pathophysiology of postacute sequelae of COVID-19 (PASC): Possible role for persistent inflammation
Gailen D. Marshall
Asia Pacific Allergy (2023) Vol. 13, Iss. 2, pp. 77-84
Open Access | Times Cited: 5
Gailen D. Marshall
Asia Pacific Allergy (2023) Vol. 13, Iss. 2, pp. 77-84
Open Access | Times Cited: 5
Effect of Paxlovid Treatment During Acute COVID-19 on Long COVID Onset: An EHR-Based Target Trial Emulation from the N3C and RECOVER Consortia
Alexander Preiss, Abhishek Bhatia, Leyna Aragon, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Alexander Preiss, Abhishek Bhatia, Leyna Aragon, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Infection-associated chronic conditions: Why Long Covid is our best chance to untangle Osler’s web
Michael J. Peluso, Maureen R. Hanson, Steven G. Deeks
Science Translational Medicine (2024) Vol. 16, Iss. 773
Open Access | Times Cited: 1
Michael J. Peluso, Maureen R. Hanson, Steven G. Deeks
Science Translational Medicine (2024) Vol. 16, Iss. 773
Open Access | Times Cited: 1
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study
Grace Qian, Xiaosong Wang, Naomi J. Patel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Grace Qian, Xiaosong Wang, Naomi J. Patel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Should We Expect an Increase in the Number of Cancer Cases in People with Long COVID?
Ana Amiama-Roig, Laura Pérez‐Martínez, Pilar Rodríguez Ledo, et al.
Microorganisms (2023) Vol. 11, Iss. 3, pp. 713-713
Open Access | Times Cited: 2
Ana Amiama-Roig, Laura Pérez‐Martínez, Pilar Rodríguez Ledo, et al.
Microorganisms (2023) Vol. 11, Iss. 3, pp. 713-713
Open Access | Times Cited: 2
Nirmatrelvir/ritonavir as a possible treatment for Long-COVID
Ignacio Pérez Catalán, Adriana Gascón Buj, Sergio García Muñoz, et al.
Revista Española de Quimioterapia (2023)
Open Access | Times Cited: 2
Ignacio Pérez Catalán, Adriana Gascón Buj, Sergio García Muñoz, et al.
Revista Española de Quimioterapia (2023)
Open Access | Times Cited: 2
Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain
Eric J. Wang, Edward Dolomisiewicz, Jay Karri, et al.
The Korean journal of pain (2023) Vol. 36, Iss. 3, pp. 299-315
Open Access | Times Cited: 2
Eric J. Wang, Edward Dolomisiewicz, Jay Karri, et al.
The Korean journal of pain (2023) Vol. 36, Iss. 3, pp. 299-315
Open Access | Times Cited: 2
Paxlovid (Nirmatrelvir/ritonavir): An Innovative Method Method for Treating Covid-19?
Prathamesh D. Wankhade -, S. G. Jawarkar -, Monika P. Jadhao -
International Journal For Multidisciplinary Research (2024) Vol. 6, Iss. 2
Open Access
Prathamesh D. Wankhade -, S. G. Jawarkar -, Monika P. Jadhao -
International Journal For Multidisciplinary Research (2024) Vol. 6, Iss. 2
Open Access
Combining Double-Dose and High-Dose Pulsed Dapsone Combination Therapy for Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome and Co-Infections, Including Bartonella: A Report of 3 Cases and a Literature Review
Richard I. Horowitz, John F. Fallon, Phyllis R. Freeman
Microorganisms (2024) Vol. 12, Iss. 5, pp. 909-909
Open Access
Richard I. Horowitz, John F. Fallon, Phyllis R. Freeman
Microorganisms (2024) Vol. 12, Iss. 5, pp. 909-909
Open Access
Expert consensus on the clinical application of oral small-molecule antiviral drugs against COVID-19
Infectious Diseases & Immunity (2024)
Open Access
Infectious Diseases & Immunity (2024)
Open Access
Long COVID for the Rheumatologist
Leonard H. Calabrese, Cassandra Calabrese
Rheumatic Disease Clinics of North America (2024) Vol. 51, Iss. 1, pp. 29-43
Closed Access
Leonard H. Calabrese, Cassandra Calabrese
Rheumatic Disease Clinics of North America (2024) Vol. 51, Iss. 1, pp. 29-43
Closed Access
Acyclovir May Be Used to Treat Certain Long COVID Patients Regardless of Herpesvirus Reactivation: Case Report
D. Stewart, Martin O. Savage
American Journal of Infectious Diseases (2024) Vol. 20, Iss. 1, pp. 1-10
Open Access
D. Stewart, Martin O. Savage
American Journal of Infectious Diseases (2024) Vol. 20, Iss. 1, pp. 1-10
Open Access
Effectiveness of early-treatment interventions on self-reported long COVID: A multi-arm, multi-stage adaptive platform control trial
Gilmar Reis, Lindsay A. Wilson, Dieter Ayers, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 1
Gilmar Reis, Lindsay A. Wilson, Dieter Ayers, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 1
Update on Central Nervous System Effects of the Intersection of HIV-1 and SARS-CoV-2
Ferron F. Ocampo, Pathariya Promsena, Phillip Chan
Current HIV/AIDS Reports (2023) Vol. 20, Iss. 6, pp. 345-356
Closed Access | Times Cited: 1
Ferron F. Ocampo, Pathariya Promsena, Phillip Chan
Current HIV/AIDS Reports (2023) Vol. 20, Iss. 6, pp. 345-356
Closed Access | Times Cited: 1
Healthcare response strategies for the long-COVID era
Hye Jun Kim, Jihun Song, Sang Min Park
Journal of Korean Medical Association (2023) Vol. 66, Iss. 1, pp. 50-59
Open Access
Hye Jun Kim, Jihun Song, Sang Min Park
Journal of Korean Medical Association (2023) Vol. 66, Iss. 1, pp. 50-59
Open Access
Long COVID treated successfully with antivirals in a rituximab-treated follicular lymphoma patient with persistent negative-antibodies to SARS-CoV2
Elias Tayar, Ryan Isber, Nidal Isber
Heliyon (2023) Vol. 9, Iss. 6, pp. e17149-e17149
Open Access
Elias Tayar, Ryan Isber, Nidal Isber
Heliyon (2023) Vol. 9, Iss. 6, pp. e17149-e17149
Open Access
